350236-32-7

Basic information

• Product Name: Benzoic acid, 3-chloro-5-iodo-2-methoxy-, methyl ester
• CAS NO: 350236-32-7
• Molecular Formula: C9H8ClIO3
• Molecular Weight: 326.518
• Mol File: 350236-32-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 3-chloro-5-iodo-2-methoxy-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 3-chloro-5-iodo-2-methoxy-, methyl ester(350236-32-7)
• EPA Substance Registry System: Benzoic acid, 3-chloro-5-iodo-2-methoxy-, methyl ester(350236-32-7)

Safety Data

• Hazardous Substances Data: 350236-32-7(Hazardous Substances Data)

Upstream product

• 40757-09-3 methyl 2-methoxy-5-iodobenzoate 

Downstream Products

• 1147116-75-3 (E)-3-chloro-2-methoxy-5-[1-(3-methoxy-7-methylbenzo[d]isoxazol-5-yl)-4-(2-oxy-oxazolidin-3-yl)-but-1-enyl]-benzoic acid methyl ester 
• 350236-34-9 3-chloro-5-iodo-2-methoxybenzoic acid 

Relevant articles and documents

Solid-phase synthesis of the alkenyldiarylmethane (ADAM) series of non-nucleoside HIV-1 reverse transcriptase inhibitors

The Sonogashira and Stille cross-coupling reactions have been employed in the synthesis of several non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the alkenyldiarylmethane (ADAM) series. The synthesis has been carried out both in solution and on a solid support. In contrast to previous syntheses of NNRTIs in the ADAM series, the present strategy allows the incorporation of differently substituted aromatic rings in a stereochemically defined fashion. The most potent of the new ADAMs inhibited the cytopathic effect of HIV-1RF in CEM-SS cell culture with an EC50 value of 20 nM.

Alkenyldiarylmethanes, Fused Analogs And Syntheses Thereof

Non-nucleoside inhibitors of HIV-1 reverse transcriptase are described. Such inhibitors may be used as part of a combination therapy to treat HIV infection. Compounds described herein exhibit antiviral potency. In addition, compounds described herein exhibit metabolic stability. Also described herein are processes for preparing Non-nucleoside inhibitors of HIV-1 reverse transcriptase.